总部位于江苏扬州的美华国际医疗科技有限公司近日成功在美国纳斯达克上市，募集资金3600万美元，成为去年滴滴赴美上市继而引发网络安全审查之后，第一家在美国上市的中国公司。大成律师事务所、The Crone Law Group担任发行人律师；金杜律师事务所、Robinson & Cole则为联席承销商提供法律意见。

美华国际医疗成立于2007年，是一家一次性医疗器械供应商，拥有I/II/III类产品920个品种、15项自主专利，销售至全国各地以及全球30多个国家和地区。

大成团队由高级合伙人李寿双牵头领导、由高级合伙人石锦娟律师、夏梓瑜律师具体执行。

该IPO项目中，Prime Number Capital、深港证券有限公司、Revere Securities、RF Lafferty & Co.担任联席承销商；奥杰律师事务所担任发行人的离岸律师。

Crone, R&C lead on first Chinese IPO in U.S. since thaw

The Crone Law Group and Dentons China have advised Meihua International Medical Technologies, a Yangzhou-headquartered medical equipment maker, on its $36 million IPO on the Nasdaq, with Robinson & Cole and King & Wood Mallesons advising the joint underwriters. 

This was the first U.S. listing by a Chinese company since last July, when Didi’s listing caused a cybersecurity-related investigation, putting such IPOs on hold. 
Established in 2007, Meihua is a supplier of disposable medical equipment, selling to more than 30 countries and regions worldwide.

The Dentons team was led by senior partner Li Shoushuang, who was assisted by senior partners Shi Jinjuan and Xia Ziyu.

The underwriters were Prime Number Capital, Shengang Securities, Revere Securities, and Rf Lafferty & Co., with Ogier acting as the issuer’s offshore lawyer.

To contact the editorial team, please email ALBEditor@thomsonreuters.com.